IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Conditions: NHL; Multiple Myeloma; Blood Cancer; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma

Interventions: Drug: IDP-023; Drug: Rituximab; Drug: Daratumumab; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Mesna

Sponsors: Indapta Therapeutics, INC.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 8, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments